In patients with metabolic abnormality-related AD, the concentration of Kallistatin is elevated, which could increase Aβ deposition through the Notch1/HES1/PPARγ/BACE1 pathway and induce tau hyperphosphorylation by activating GSK-3β. Here, HES1 is linked to Alzheimer disease.